Opinion

Video

CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection

Author(s):

Caron A. Jacobson, MD, MMSc,Peter Riedell, MD

Experts discuss sequencing treatments in the third-line setting or beyond for patients who have not received chimeric antigen receptor T-cell therapy (CAR T) previously, comparing bispecific antibodies, CAR T, and other agents like polatuzumab and tafasitamab, while also considering patient factors and disease characteristics when selecting among available CAR-T options (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], and tisagenlecleucel [tisa-cel]).

Video content above is prompted by the following:

  • In the third-line setting or beyond, for those who did not receive CAR T previously, how are you sequencing among bispecific antibodies, CAR T, and other available agents (eg, polatuzumab, tafasitamab)?
  • What patient factors or disease characteristics do you take into account when choosing among the available CAR T-cell therapy options (axi-cel, liso-cel, tisa-cel?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
Video

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

May 14th 2025 - May 15th 2026

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

May 13th 2025 - Jun 18th 2025

online-activity
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity
View More
Related Content